Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Cash & Equivalents

Cash & Equivalents at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$173.38M-34.4%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$175M+37.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$882.02M+62.5%
Arrowhead Research logo
Arrowhead ResearchARWR
$188.52M+1.5%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$113.6M+43.9%
ALN
Alnylam PharmaceuticalsALNY
$1.71B+67.5%

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's cash & equivalents?
BioCryst Pharmaceuticals (BCRX) reported cash & equivalents of $173.38M in Q1 2026.
How has BioCryst Pharmaceuticals's cash & equivalents changed year-over-year?
BioCryst Pharmaceuticals's cash & equivalents increased by 62.2% year-over-year, from $106.88M to $173.38M.
What is the long-term trend for BioCryst Pharmaceuticals's cash & equivalents?
Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's cash & equivalents has grown at a -19.6% compound annual growth rate (CAGR), from $272.13M to $91.34M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.